Sort by

Send to

Choose Destination

Links from PubMed

Items: 20


Influence of health warnings on the use of rosiglitazone and pioglitazone in an area of Spain: A time-series study.

Carracedo-Martínez E, Pia-Morandeira A.

SAGE Open Med. 2016 Aug 16;4:2050312116653054. doi: 10.1177/2050312116653054. eCollection 2016.


Disparities in Discontinuing Rosiglitazone Following the 2007 FDA Safety Alert.

Qato DM, Trivedi AN, Mor V, Dore DD.

Med Care. 2016 Apr;54(4):406-13. doi: 10.1097/MLR.0000000000000502.


Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs.

Ahuja V, Sohn MW, Birge JR, Syverson C, Budiman-Mak E, Emanuele N, Cooper JM, Huang ES.

J Manag Care Spec Pharm. 2015 Dec;21(12):1214-34.


Rosiglitazone use and associated adverse event rates in Canada: an updated analysis.

Iczkovitz S, Dhalla D, Terres JA.

BMC Res Notes. 2015 Sep 29;8:505. doi: 10.1186/s13104-015-1448-6.


Stimulated reporting: the impact of US food and drug administration-issued alerts on the adverse event reporting system (FAERS).

Hoffman KB, Demakas AR, Dimbil M, Tatonetti NP, Erdman CB.

Drug Saf. 2014 Nov;37(11):971-80. doi: 10.1007/s40264-014-0225-0.


Identifying plausible adverse drug reactions using knowledge extracted from the literature.

Shang N, Xu H, Rindflesch TC, Cohen T.

J Biomed Inform. 2014 Dec;52:293-310. doi: 10.1016/j.jbi.2014.07.011. Epub 2014 Jul 19.


Utilisation trends of rosiglitazone and pioglitazone in Australia before and after safety warnings.

Niyomnaitham S, Page A, La Caze A, Whitfield K, Smith AJ.

BMC Health Serv Res. 2014 Apr 4;14:151. doi: 10.1186/1472-6963-14-151.


Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012.

Turner LW, Nartey D, Stafford RS, Singh S, Alexander GC.

Diabetes Care. 2014 Apr;37(4):985-92. doi: 10.2337/dc13-2097. Epub 2013 Nov 6.


Rosiglitazone use and post-discontinuation glycaemic control in two European countries, 2000-2010.

Ehrenstein V, Hernandez RK, Ulrichsen SP, Rungby J, Lash TL, Riis AH, Li L, Sørensen HT, Jick SS.

BMJ Open. 2013 Sep 24;3(9):e003424. doi: 10.1136/bmjopen-2013-003424.


Changing prescribing patterns of type 2 diabetes medications from 2002-2010: an electronic health record-based evaluation.

Mehta SN, Goldfine AB, Abrahamson MJ, DiVincenzo R, Laffel LM.

J Diabetes Sci Technol. 2013 Jan 1;7(1):119-22.


Variation in medication adherence in heart failure.

Zhang Y, Wu SH, Fendrick AM, Baicker K.

JAMA Intern Med. 2013 Mar 25;173(6):468-70. doi: 10.1001/jamainternmed.2013.2509. No abstract available.


Association between unemployment rates and prescription drug utilization in the United States, 2007-2010.

Kozman D, Graziul C, Gibbons R, Alexander GC.

BMC Health Serv Res. 2012 Nov 30;12:435. doi: 10.1186/1472-6963-12-435.


Association between longer therapy with thiazolidinediones and risk of bladder cancer: a cohort study.

Mamtani R, Haynes K, Bilker WB, Vaughn DJ, Strom BL, Glanz K, Lewis JD.

J Natl Cancer Inst. 2012 Sep 19;104(18):1411-21. Epub 2012 Aug 9.


Getting out of a sticky situation: targeting the myofibroblast in scleroderma.

Leask A.

Open Rheumatol J. 2012;6:163-9. doi: 10.2174/1874312901206010163. Epub 2012 Jun 15.


Cardiovascular disease risk reduction by raising HDL cholesterol--current therapies and future opportunities.

Mahdy Ali K, Wonnerth A, Huber K, Wojta J.

Br J Pharmacol. 2012 Nov;167(6):1177-94. doi: 10.1111/j.1476-5381.2012.02081.x. Review.


Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review.

Dusetzina SB, Higashi AS, Dorsey ER, Conti R, Huskamp HA, Zhu S, Garfield CF, Alexander GC.

Med Care. 2012 Jun;50(6):466-78. doi: 10.1097/MLR.0b013e318245a160. Review.


State Medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warning.

Ross JS, Jackevicius C, Krumholz HM, Ridgeway J, Montori VM, Alexander GC, Zerzan J, Fan J, Shah ND.

Health Aff (Millwood). 2012 Jan;31(1):188-98. doi: 10.1377/hlthaff.2011.1068.


The pragmatist's guide to comparative effectiveness research.

Chandra A, Jena AB, Skinner JS.

J Econ Perspect. 2011 Spring;25(2):27-46.


Drug vs class-specific black box warnings: does one bad drug spoil the bunch?

Dusetzina SB, Caleb Alexander G.

J Gen Intern Med. 2011 Jun;26(6):570-2. doi: 10.1007/s11606-011-1714-9. No abstract available.


Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies.

Loke YK, Kwok CS, Singh S.

BMJ. 2011 Mar 17;342:d1309. doi: 10.1136/bmj.d1309. Review.

Items per page

Supplemental Content

Write to the Help Desk